Alan Weintraub, MD
Gastroenterology · Tampa, FLNPI 1780609065
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,384 of the $2,947 with a category attached, or 80.9%. 25 manufacturers reported payments, led by AbbVie at 42.9% of the total. Reporting peaked in 2023 at $864 and has fallen 54.1% since, to $397 in 2025. That places this record below the midpoint for gastroenterology clinicians in FL, where the typical reported total is $3,025.
Across 152 payments — averaging $19.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Janssen Research & Development, LLC$383
- Johnson & Johnson$343
- Novo Nordisk$293
- Janssen Scientific Affairs, LLC$98
- Pfizer$71
- plus $494 from 19 others
Across 696 payments — averaging $6740.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.2M
- Janssen Research & Development, LLC$1.1M
- Sanofi US Services Inc.$969K
- AbbVie$661K
- Takeda Pharmaceuticals U.S.A., Inc.$520K
- Eli Lilly$248K
What the payments were for
- Consulting fees$130%
- Travel & lodging$38313%
- Food & beverage$2,38481%
- Education$1676%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 91 | $1,265 |
| Janssen Research & Development, LLC | 1 | $383 |
| Johnson & Johnson(2 entities) | 13 | $343 |
| Novo Nordisk | 14 | $293 |
| Janssen Scientific Affairs, LLC | 1 | $98 |
| Pfizer | 4 | $71 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $62 |
| Amgen | 4 | $62 |
| Celltrion USA Inc. | 2 | $45 |
| Abbott | 2 | $39 |
| Bristol Myers Squibb | 2 | $29 |
| Gilead | 2 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $22 |
| Vertos Medical, Inc. | 1 | $22 |
| Bayer | 1 | $20 |
| GSK | 1 | $20 |
| Merck | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $18 |
| Lucid Diagnostics Inc. | 1 | $16 |
| Cleerly, Inc. | 1 | $14 |
| Intercept Pharmaceuticals, Inc. | 1 | $13 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Evoke Pharma, Inc. | 1 | $12 |
How this compares
$2,947 in reported general payments places this provider in the 45th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 22 | $23,654 |
| LinzessLinaclotide | 14 | $12,526 |
| EliquisApixaban | 14 | $8,598 |
| Omeprazole | 332 | $4,160 |
| Famotidine | 221 | $4,043 |
| Pantoprazole Sodium | 295 | $3,539 |
| Sucralfate | 28 | $3,202 |
| Dexlansoprazole DrDexlansoprazole | 11 | $1,596 |
| Esomeprazole Magnesium | 30 | $1,113 |
| Rabeprazole Sodium | 27 | $1,006 |
| Dicyclomine Hcl | 43 | $758 |
| Prednisone | 67 | $518 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 17 | $445 |
| Potassium Chloride | 21 | $346 |
| Naproxen | 28 | $291 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $22 | $23,65422 claims |
| AbbVieLinzess | $1,265 | $12,52614 claims |
| PfizerEliquis | $71 | $8,59814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,388 gastroenterology providers in Florida.
Other gastroenterology in Tampa
- Adnan MuhammadTampa$150K
- John JacobsTampa$141K
- Renee Marchioni BeeryTampa$126K
- Michael DanielTampa$52K
- Samuel GidayOrlando$2M
- Lukasz KwapiszMiami$1.2M
- Jennifer Seminerio-DiehlOrlando$1.1M
- Udayakumar NavaneethanSaint Petersburg$1.1M
- Ronen AraiCoral Springs$1.1M
- Charles SninskyGainesville$983K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.